Replies to post #3162 on Delcath Systems Inc (DCTH)

[ash111]

Always good to check 10Q completely to avoid cherry picking information, http://delcath.com/sec-filings/ :

Highlights:

1. As of August 12, 2016, 1,521,933 shares of the Company’s common stock, $0.01 par value, were outstanding.

2.Cash and cash equivalents: $ 7,484 (in millions)
Restricted cash $ 17,162 (in millions)
Restricted cash, net of current portion $ 13,100(in millions)

that's almost $40m. vs $4.5 Cap ( at 3 pps w/1.5m O/S), or $5.8m (at 3 pps w/1.9m O/S+ add more $1.3m in Cash). That's more than $20 PPS.

3. Initial Commercialization,deep in EU market (pgs. 8): http://delcath.com/wp-content/uploads/2016/07/DCTH_ASM_July2016-FINAL.pdf
+ more events till year end + mentioned recently as a major key player for a Bike Duct Cancer among a few big names companies... http://finance.yahoo.com/news/world-bile-duct-cancer-cholangiocarcinoma-150500717.html

4. FDA approval since 2015 : “orphan drug designation” for melphalan for the treatment of cholangiocarcinoma, a type of liver cancer that affects bile".. "Orphan drug designation status provides some exclusivity benefits, tax credits for some research and a waiver of the FDA “new drug application” user fee, according to a prepared statement.ducts. http://poststar.com/business/local/delcath-receives-new-fda-approval/article_0d206ce0-cfe0-5fa2-97cc-d7c911d1848d.html

that's why i'm long. Immense undervalued and bottomed.